Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S0140-6736(15)01109-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparative performance of four rapid Ebola antigen-detection lateral flow immunoassays during the 2014-2016 Ebola epidemic in West Africa.
PLoS One
January 2020
Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland.
Background: Without an effective vaccine, as was the case early in the 2014-2016 Ebola Outbreak in West Africa, disease control depends entirely on interrupting transmission through early disease detection and prompt patient isolation. Lateral Flow Immunoassays (LFI) are a potential supplement to centralized reference laboratory testing for the early diagnosis of Ebola Virus Disease (EVD). The goal of this study was to assess the performance of commercially available simple and rapid antigen detection LFIs, submitted for review to the WHO via the Emergency Use Assessment and Listing procedure.
View Article and Find Full Text PDFAnalytical Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection.
J Infect Dis
October 2016
Department of Microbiology and Immunology Zalgen Labs, Germantown, Maryland.
Background: Ebola virus disease (EVD) is a severe viral illness caused by Ebola virus (EBOV). The 2013-2016 EVD outbreak in West Africa is the largest recorded, with >11 000 deaths. Development of the ReEBOV Antigen Rapid Test (ReEBOV RDT) was expedited to provide a point-of-care test for suspected EVD cases.
View Article and Find Full Text PDFField Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection.
J Infect Dis
October 2016
Department of Microbiology and Immunology Zalgen Labs, Germantown, Maryland.
Background: The 2013-2016 West African Ebola virus disease (EVD) epidemic is the largest recorded. Triage on the basis of clinical signs had limited success, and the time to diagnosis by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) could exceed 5 days. Here we describe the development and field validation of the ReEBOV Antigen Rapid Test (ReEBOV RDT) to aid triage of individuals with suspected EVD.
View Article and Find Full Text PDFReEBOV Antigen Rapid Test kit for Ebola - Authors' reply.
Lancet
December 2015
Partners in Health, Boston, MA, USA; Boston Children's Hospital, Boston, MA 02115, USA. Electronic address:
ReEBOV Antigen Rapid Test kit for Ebola.
Lancet
December 2015
Médecins Sans Frontières, Brussels, Belgium.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!